Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

Tumor vessels identified by unique molecular markers

Results from a new study have made it easier for scientists to distinguish between growing blood vessels in healthy tissues and those that are associated with tumors.

16 Jun 2007

New Rochester program to coordinate patient care, research for patients suffering with brain and spinal tumors

The University of Rochester Medical Center and its Department of Neurosurgery are establishing a new multidisciplinary program to coordinate patient care, research and community outreach efforts for patients suffering with brain and spinal tumors.

8 Jun 2007

Angiogenesis gene polymorphisms predict tumor recurrence in stage II and III colon cancer

Researchers at the University of Southern California (USC) have identified specific molecular markers that may help to predict tumor recurrence in stage II and III colon cancer patients.

8 Jun 2007

Combination therapy reduces tumor resistance to radiation

Radiation is used to treat a variety of tumors and the response of tumors to radiation is dependent on endothelial cell death, which in turn limits oxygen delivery to the tumor, causing hypoxia and tumor cell death.

8 Jun 2007

VEGF Trap (aflibercept) shows activity in patients with advanced ovarian cancer

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Axitinib shows promise in treatment of advanced thyroid cancer

The investigational drug axitinib produced tumor regression or stable disease in almost three-out-of-four patients with advanced thyroid cancer, a research team reported at the annual meeting of the American Society for Clinical Oncology in Chicago.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007

CRT and Manchester University announce biomarker alliance with AstraZeneca

Cancer Research Technology Limited (CRT), the cancer-focused development and commercialisation company, and The University of Manchester today announce the establishment of an alliance with AstraZeneca to develop serological pharmacodynamic (PD) biomarkers.

4 Jun 2007

Temsirolimus, effective new treatment for advanced renal cell carcinoma

The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.

1 Jun 2007

Decoding gene expression in cancer tumors using noninvasive imaging

By correlating images of cancerous liver tissue with gene expression patterns, a research team led by a radiologist at the University of California, San Diego (UCSD) School of Medicine has developed tools that may some day allow physicians to view a CT image of a cancer tumor and discern its genetic activity.

22 May 2007

Link between periodontitis and tongue cancer

Researchers at the University at Buffalo and Roswell Park Cancer Institute have shown for the first time that an association exists between long-standing periodontitis, or gum disease, and risk of tongue cancer.

22 May 2007

Novel therapies to prevent metastasis

In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the tumor.

8 May 2007

Two-photon absorption imaging of hemoglobin

In an advance that can potentially assist cancer diagnosis, a new optical technique provides high-resolution, three-dimensional images of blood vessels by taking advantage of the natural multiple-photon-absorbing properties of hemoglobin, the red-blood-cell molecule that carries oxygen throughout the bloodstream.

1 May 2007

Chronic alcohol consumption increases tumor growth and amgiogenesis of breast cancer in female mice

For the first time, scientists have used a laboratory mouse model to mimic the development of human alcohol-induced breast cancer.

30 Apr 2007

Drug for toenail fungus also blocks angiogenesis

Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers.

30 Apr 2007

Chemicals in cruciferous vegetables may provide cancer-fighting benefit

Chemicals in cruciferous vegetables, such as broccoli, watercress, cabbage and cauliflower, appear to not only stop human prostate cancer cells from growing in mice but also may cut off the formation of blood vessels that "feed" tumors, says a University of Pittsburgh Cancer Institute study.

18 Apr 2007

Lexicon Reports on anti-angiogenesis target discoveries

Lexicon Genetics has presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007